VIA
ANIK icon

Virtus Investment Advisers’s Anika Therapeutics ANIK Stock Holding History

Virtus Investment Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-45,579
Closed -$1.15M – 343
2024
Q2 		$1.15M Hold
45,579
– – 0.98% 12
2024
Q1 		$1.16M Hold
45,579
– – 0.83% 22
2023
Q4 		$1.03M Hold
45,579
– – 0.77% 27
2023
Q3 		$849K Hold
45,579
– – 0.58% 39
2023
Q2 		$1.18M Hold
45,579
– – 0.8% 24
2023
Q1 		$1.31M Buy
45,579
+29,493
+183% +$878K 0.92% 23
2022
Q4 		$476K Buy
+16,086
New +$458K 0.32% 96

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus Investment Advisers's ANIK Position: Q3 2024 in Review

Virtus Investment Advisers sold out of Anika Therapeutics (ANIK) in Q3 2024, closing a stake of 45,579 shares — an estimated $1.15M sold.

Virtus Investment Advisers first reported a position in ANIK in Q4 2022 and held it in 7 quarters. The position peaked at $1.31M in Q1 2023. 122 funds tracked by Wall St. Rank hold ANIK as of Q3 2024.

  • Virtus Investment Advisers reported no remaining Anika Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Virtus Investment Advisers sold 45,579 Anika Therapeutics shares in Q3 2024, an estimated $1.15M.
  • Virtus Investment Advisers first reported a position in Anika Therapeutics in Q4 2022 and held it in 7 quarters.
  • Virtus Investment Advisers's Anika Therapeutics position peaked at $1.31M in Q1 2023.
  • 122 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2024.

Based on Virtus Investment Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.